Common Characteristics in RA Patients Who Don’t Respond to Biologics
FDA Greenlights Osteoporosis Drug for Postmenopausal Women
Upadacitinib at the FDA
Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA
FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
Can IL-6 Predict Sarilumab Response?
Bimekizumab Promising for PsA
Long-Term Data Show Baricitinib Is Safe & Effective for RA
Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector
- 1
- 2
- 3
- …
- 16
- Next Page »